Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ankaferd Blood Stopper
- Development stage
- Phase 4
- Lead developer
- AND İlaç
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical, Oral
01
Overview
**Ankaferd Blood Stopper** is a locally applied Turkish herbal hemostatic medicine comprising standardized extracts from five plants: *Thymus vulgaris*, *Glycyrrhiza glabra*, *Vitis vinifera*, *Alpinia officinarum*, and *Urtica dioica*. It is intended to control bleeding by rapidly producing an encapsulated protein network at the bleeding site that promotes erythrocyte aggregation; this effect is reported to involve fibrinogen-associated protein interactions rather than direct correction of individual coagulation-factor deficiencies. The product has been approved and licensed in Turkey for management of external hemorrhage and bleeding during dental procedures, and it has been studied or used locally in surgical, dental, gastrointestinal, and epistaxis-related bleeding settings. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18304416/))
- Brand names
- Ankaferd Blood StopperAnkaferd BloodStopper
- Other names
- Ankaferd HemostatABS
02
Targets
Actin filament proteinsFGG (Fibrinogen gamma chain)F2 (Thrombin)
Beyond the preview
Go deeper on Ankaferd Blood Stopper.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ankaferd Blood Stopper.